Navigation Links
Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
Date:5/6/2010

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its financial results for the first quarter ended March 31, 2010 on Monday, May 10th after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host a call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 573-4752 (domestic) or (617) 224-4324 (international), participant code 75892043. The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and the Company has submitted a New Drug Application to the FDA.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
2. Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
3. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
4. Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
5. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
6. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
7. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
8. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
Breaking Medicine Technology:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):